Scale up and commersialisation of an automatic production method for astatinated cancer pharmaceuticals
| Reference number | |
| Coordinator | Alpha Therapy Solutions AB |
| Funding from Vinnova | SEK 749 195 |
| Project duration | April 2020 - November 2022 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
Important results from the project
The purpose of this project was to develop an automated production module for astatinated pharmaceuticals for clinical studies and, by extension, patient treatments of disseminated cancer. The goal was to develop a new solution that can improve the possibilities for research with astatine-211, as well as for the development of new astatinated drugs for the treatment of various types of disseminated cancer. The aim and goal of the project has been fulfilled, and the developed technology now has the potential to create value within this segment, both in Sweden and internationally.
Expected long term effects
Within the project, the commercial C100 module was developed and tested, and the product will be CE-marked before the end of 2022. The product will be used in a first clinical study this year, here in Sweden, where an astatinated radiopharmaceutical will be evaluated for the treatment of metastatic ovarian cancer. A number of C100 modules will be installed in labs and research centers around the world in 2023, and these will be used for research purposes, but also for various clinical studies.
Approach and implementation
The project was carried out in collaboration primarily between Atley Solutions (formerly Alpha Therapy Solutions) and Sahlgrenska Universitetssjukhuset - Medicinsk Fysik and Teknik - Diagnostisk Strålningsfysik (MFT-DSF). In addition to the two project parties, a couple of different subcontractors were also involved such as FutureChemistry, Qing and Synergon. Overall, the work has went well, but there have been a couple of significant delays, primarily due to various delays in technology development.